Lead program in sufferers with lymphoma demonstrated preliminary security and efficacy outcomes with sustained full response in first research participant handled with MT-601 (Neldaleucel) following CAR T relapse Secured non-dilutive…
Tag:
Lead program in sufferers with lymphoma demonstrated preliminary security and efficacy outcomes with sustained full response in first research participant handled with MT-601 (Neldaleucel) following CAR T relapse Secured non-dilutive…